Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

biOasis Technologies Ord Shs V.BTI.H

Alternate Symbol(s):  BIOAF

Bioasis Technologies Inc. is a Canada-based biopharmaceutical company focused on research and development of technologies and products intended for the treatment of patients with nervous system, including central nervous system, diseases and disorders. The Company is engaged in the development of its xB 3 platform, which is a peptide-based technology, for the transport of therapeutic agents, in particular biological products, across the blood-brain barrier (BBB). It is focused on both orphan drug indications, including brain cancers, and rare genetic neurodegenerative diseases and neuroinflammatory conditions. The Company is also focused on its Epidermal Growth Factor (EGF) platform for treating rare and orphan neurodegenerative and neuroinflammatory disorders. EGF is a protein that stimulates cell growth and differentiation, notably for myelin producing cells. Its development programs include xB3-001: Brain Metastases, xB3-002: Glioblastoma and xB3-007: Neurodegenerative Disease.


TSXV:BTI.H - Post by User

Comment by JDavenporton Oct 01, 2022 11:10am
141 Views
Post# 34999322

RE:RE:RE:RE:RE:RE:RE:Prothena and Management's Reporting

RE:RE:RE:RE:RE:RE:RE:Prothena and Management's ReportingHere's a question for you. Has any licensee or partner ever made a milestone payment? Which prompts the question, has any partner or licensee ever reached a milestone? Chiesi, in over two years, has never reached a developmental milestone? None?

If no partner or licensee has reached a milestone, have any given up trying to do so?

So you can say that Bioasis obviously needs more time but how does one reconcile that with the short timeline of the Janssen agreement and its reference to multiple programs? Why is Chiesi in its third year and still has not reported a developmental milestone? The original press release and the webcast talked about developmental, regulatory and commercial milestones. 

I've been asking these questions in one form or another since 2015.

jd
<< Previous
Bullboard Posts
Next >>